SecBot SecBot

NSPR

InspireMD, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001433607 Healthcare & Medical Devices
$0.4350 −0.01 (−3.33%)
Oct 27 4:00 PM ET · prev $0.4500
Market cap
$21.2M
Nano cap
Median target
$3.00
+590% · range $3.00–4.00
Next earnings
Nov 10
in 14 days · EPS est. −$0.15
1 year
−80.8%
from $2.26 · Oct 27
30 days
−37.0%
from $0.6900
52-week range
$0.4350–2.29
at the low
Avg volume 20D
201.5K
Oct 21 spike 850.7K
Short interest
🔒 Subscribers only
Insider net
+$243.8K
4 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BEARISH 6 reports · 90 days
Balance 2 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/6 ·Next Earnings date, Nov 10, 2026
Strongest MIXED InspireMD amended existing Series J and Series K warrants with certain holders, lowering the exercise price…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $370.8K at an average $1.15. 1 insider sold $127.0K. Price is 62% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 7 added (0 new), 2 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.187 → −$0.153 over 90 days. 3 up, 0 down in 30 days.

  • TrendDOWNTREND

    37% below its 50-day average. New closing low $0.4350 on Oct 27.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADAADD247—
BlackRock, Inc.ADD122,993$86.1K
RENAISSANCE TECHNOLOGIES LLCDOUBLED112,832$79.0K
Creative PlanningDOUBLED108,964$76.3K
Centiva Capital, LPADD44,123$30.9K
MILLENNIUM MANAGEMENT LLCTRIM37,677$26.4K
MORGAN STANLEYTRIM28,371$19.9K
OSAIC HOLDINGS, INC.ADD15,952$11.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +590%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
May 5, 2026Piper Sandler
REITERATE
REITERATEOverweight

Insider ledger

Form 4
$370.8K
bought · 4 insiders
$127.0K
sold · 1 insider
−62.3%
vs their $1.15 cost
DateInsiderTypeValue
Sep 18, 2026
BERMAN MICHAEL
Director
OTHER30,625 sh
Sep 18, 2026
BERMAN MICHAEL
Director
OTHER61,248 sh
Sep 18, 2026
ROUBIN GARY S
Director
OTHER15,313 sh
Sep 18, 2026
ROUBIN GARY S
Director
OTHER30,624 sh
Sep 18, 2026
Stuka Paul
Director
OTHER87,500 sh
Sep 18, 2026
Stuka Paul
Director
OTHER43,750 sh
May 27, 2026
Stuka Paul
Director
BUY$17.5K
May 19, 2026
Gleason Shane Thomas
Chief Commercial Officer
SELL$23.0K

Earnings setup

Estimates
Nov 10
reports in 14 days
−$0.15
EPS estimate, this quarter
+18%
estimate change, 90 days
3↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.16–-$0.15+17.9%$2.0M
Next Q-$0.13-$0.14–-$0.12+31.6%$2.7M
Current FY-$0.45-$0.63–-$0.13+38.7%$9.8M
Next FY-$0.48-$0.52–-$0.45+20.8%$20.1M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 21, 2026 SEC
InspireMD amended existing Series J and Series K warrants with certain holders, lowering the exercise price to $0.7674…
8-K — Impact 5/10
Sep 21, 2026 Press
InspireMD amended existing Series J and K warrants to align exercise with anticipated FDA approval of CGuard Prime 80…
Impact 5/10
Sep 21, 2026 Activist
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime
Sep 18, 2026 Insider
BERMAN MICHAEL disposed of 30,625 shares
Director
Sep 18, 2026 Insider
BERMAN MICHAEL disposed of 61,248 shares
Director
Sep 18, 2026 Insider
ROUBIN GARY S disposed of 15,313 shares
Director
Aug 17, 2026 SEC
InspireMD's Q2 2026 revenue was essentially flat YoY at $1.77M, missing the $2.1M consensus estimate due to a…
8-K — Impact 6/10
Aug 17, 2026 SEC
InspireMD reported Q2 2026 revenue of $1.77M, essentially flat YoY, and a net loss of $0.17 per share, beating…
PRESS-RELEASE — Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
NSPR Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 21, 2026
Activist
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate…
Sep 4, 2026
Press release
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid…
Aug 17, 2026
Earnings
InspireMD Reports Second Quarter 2026 Financial Results
- Company to host investor conference call today, August 17 th , at 8:30am EDT -
Aug 17, 2026
Earnings date
NSPR Q2 2026 Earnings Scheduled — 2026-08-17
Aug 11, 2026
Earnings date
NSPR Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

15 filings · 4 press releases · 2 bullish · 5 bearish · 1 mixed · 7 neutral
All NSPR filing & press-release reports (19)